| Project/Area Number |
17H07282
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Cardiovascular medicine
|
|---|
| Research Institution | Kobe Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
SASAKI NAOTO
|
|---|
| Project Period (FY) |
2017-08-25 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 心筋梗塞 / 心不全 / 炎症・免疫反応 / 紫外線照射 / 制御性T細胞 / CCR4 |
|---|
| Outline of Final Research Achievements |
Atherosclerotic cardiovascular disease and its related heart failure are major causes of mortality in developed countries. It is important to explore the pathophysiology and develop effective therapeutic approaches to preventing these diseases. Chronic inflammation is critically involved in the pathogenesis of atherosclerotic disease and heart failure. Regulatory T cells have been shown to play a protective role in the development of heart failure by regulating immunoinflammatory responses. Using a mouse model of myocardial infarction, we demonstrated that ultraviolet B irradiation to the skin could reduce the development and related mortality of heart failure after myocardial infarction, associated with systemic expansion of regulatory T cells and suppressed inflammation in the infarcted heart.
|
| Academic Significance and Societal Importance of the Research Achievements |
我が国での心筋梗塞や脳梗塞などの動脈硬化性疾患は、癌についで死亡原因の第２位となっており、これらの発症機序を解明し、有効な治療法や予防法を開発することが切に望まれている。UVB照射は、皮膚疾患治療の病状の改善に有効な治療法として確立されている。近年、動脈硬化性疾患や心筋梗塞後の心不全に対する治療は医療経済を圧迫しているが、UVB照射による治療は経済的負担の少ない治療法と期待される。今後、病態改善の詳細な機序や、病態改善に効果的な波長や照射条件を明らかにすることにより、新規治療法としての臨床応用が期待される。
|
